Candel Therapeutics, INC 8-K filings

Candel Therapeutics announced Q2 2026 results, highlighting progress in its aglatimagene prostate cancer program with a planned BLA submission in Q4 2026 and positive Phase 3 data published in The Lancet Oncology.

Candel Therapeutics stockholders re-elected four Class II directors and ratified the appointment of KPMG LLP as the company's independent auditor.

Candel Therapeutics, Inc. has formalized the employment terms for its Chief Financial Officer, Charles Schoch, detailing salary, bonus, and severance provisions.

Candel Therapeutics announced Q1 2026 financial results, highlighting progress towards a Q4 2026 BLA submission for aglatimagene in prostate cancer and positive extended survival data in NSCLC.

Candel Therapeutics announced its Q4 and full-year 2025 financial results, highlighted by significant progress in its clinical pipeline, including plans for a pivotal Phase 3 trial for aglatimagene in NSCLC and a BLA submission for prostate cancer.

Candel Therapeutics announced the pricing of an underwritten public offering of 18.3 million common shares at $5.45 each, aiming to raise $100 million for clinical development and commercialization.

Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, LP, contingent on FDA approval of CAN-2409 for prostate cancer.

Candel Therapeutics presented positive clinical trial results for its lead immunotherapy candidates, CAN-2409 and CAN-3110, outlining a clear path to regulatory submission and commercialization.

Candel Therapeutics announced its third quarter 2025 financial results, highlighted by progress in its CAN-2409 and CAN-3110 clinical programs and a new $130 million term loan facility.

Candel Therapeutics announced a new $130 million term loan facility and positive interim data from its CAN-3110 glioblastoma clinical trial, while strategically focusing on prostate and NSCLC cancer programs.

Candel Therapeutics, Inc. extended its lease for its Needham, Massachusetts premises by three years to August 31, 2029, with new escalating annual base rent.

Candel Therapeutics announced its second quarter 2025 financial results and provided key updates on its clinical programs, including significant progress for CAN-2409 in prostate cancer.

Candel Therapeutics, a clinical-stage biopharmaceutical company, announced a registered direct offering of approximately 3.2 million common shares at $4.67 per share, raising an estimated $15.0 million to fund pre-commercialization activities for its lead prostate cancer therapy, CAN-2409, and other corporate purposes.

Candel Therapeutics, a clinical-stage biopharmaceutical company, has officially appointed Charles Schoch as its Chief Financial Officer, recognizing his instrumental role in the company's financial management and recent successful capital raise.

Candel Therapeutics, Inc. announced that its stockholders successfully re-elected three Class I directors and ratified KPMG LLP as its independent registered public accounting firm for the 2025 fiscal year at the Annual Meeting held on June 17, 2025.

Candel Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Maha Radhakrishnan to its Board of Directors, bringing extensive industry experience to support the company's late-stage oncology programs and anticipated Biologics License Application submission for CAN-2409.

Candel Therapeutics announced that its lead immunotherapy candidate, CAN-2409, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for the treatment of newly diagnosed localized prostate cancer, based on positive Phase 3 clinical trial data.

Candel Therapeutics announces positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer, demonstrating a statistically significant improvement in disease-free survival.

Candel Therapeutics reports positive phase 3 clinical trial results for CAN-2409 in localized prostate cancer and provides a corporate update along with its first quarter 2025 financial results.

Candel Therapeutics will present positive Phase 3 clinical trial data for CAN-2409 in localized prostate cancer at the ASCO 2025 Annual Meeting.

Candel Therapeutics reports positive final survival data from its Phase 2a clinical trial of CAN-2409 in patients with advanced non-small cell lung cancer (NSCLC) who have shown inadequate response to Immune Checkpoint Inhibitor (ICI) treatment.

Candel Therapeutics reports positive data from a pivotal Phase 3 trial for CAN-2409 in prostate cancer and announces its full year 2024 financial results, highlighting a transformational year for the company.

Candel Therapeutics reports positive final overall survival data from its Phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer, showing a significant improvement in survival compared to the control group.

Candel Therapeutics announced a strong cash position of $102.9 million and highlighted key milestones for 2025, including upcoming data readouts and BLA preparations.

Candel Therapeutics has launched an $80 million public offering of common stock and pre-funded warrants to fund the development of its cancer immunotherapy pipeline.

Candel Therapeutics announced positive topline results from its Phase 3 trial of CAN-2409 in intermediate-to-high risk prostate cancer, demonstrating a statistically significant improvement in disease-free survival, while a Phase 2b trial in low-to-intermediate risk prostate cancer did not meet its primary endpoint.

Candel Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical programs, including expected topline data readouts for CAN-2409 in prostate cancer in Q4 2024.

Candel Therapeutics reports encouraging survival data and immune response from its CAN-3110 trial in recurrent high-grade glioma, presented at the International Oncolytic Virotherapy Conference.

Candel Therapeutics reported positive survival data from its CAN-2409 trials in pancreatic and lung cancer, along with second quarter financial results and key corporate updates.

Candel Therapeutics held its annual meeting on June 26, 2024, electing three Class III directors and ratifying KPMG LLP as its independent auditor for the fiscal year ending December 31, 2024.